Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicentre, Phase 2a Study to Assess Target Engagement, Safety and Tolerability of AZD4831 in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

Next Previous
Trial Profile

A Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicentre, Phase 2a Study to Assess Target Engagement, Safety and Tolerability of AZD4831 in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mitiperstat (Primary)
  • Indications Heart failure
  • Focus Biomarker; Therapeutic Use
  • Acronyms SATELLITE
  • Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

  • 02 Feb 2024 (https://onlinejcf.com/article/S1071-9164(23)00142-2/fulltext#:~:text=Myeloperoxidase%20inhibition%20is%20hypothesized%20to,in%20patients%20with%20HFpEF%2FHFmrEF.) MPO activity related to potentially improve heart function and clinical outcome, so added focus as TU
  • 01 Jan 2024 Primary endpoint has been met. (The change from baseline in MPO activity in % after AZD4831 treatment.), as per Results published in the Journal of Cardiac Failure
  • 01 Jan 2024 Results published in the Journal of Cardiac Failure

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top